Leech-derived thrombin inhibitors: From structures to mechanisms to clinical applications

Journal of Medicinal Chemistry

Volumn 53, Issue 10, 2010, Pages 3847-3861

  Corral Rodríguez, María Ángeles ^a   MacEdo Ribeiro, Sandra ^b   Barbosa Pereira, Pedro José ^b   Fuentes Prior, Pablo ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTISTASIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; BOROLOG; DESULFATOHIRUDIN; HAEMADIN; HEPARIN; HIRUDIN; HIRUDISIN; HIRUGEN; HIRULOG; HIRUNORM; HIRUTONIN; LEPIRUDIN; THEROMIN; THEROSTASIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; AMINO ACID SEQUENCE; ANTICOAGULATION; BLEEDING; DRUG ACTIVITY; DRUG INHIBITION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; HYDROGEN BOND; LEECH; NONHUMAN; REVIEW; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; ANIMALS; FACTOR XA; FIBRINOLYTIC AGENTS; HIRUDINS; INVERTEBRATE HORMONES; LEECHES; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEINS; THROMBIN;

EID: 77952738973     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901743x     Document Type: Review

References (147)

1. Fields, W. S. The history of leeching and hirudin Haemostasis 1991, 21, 3-10
2. Ernst, E. Born to suck. The return of the leech? Pain 2008, 137, 235-236
3. Whitaker, I. S.; Izadi, D.; Oliver, D. W.; Monteath, G.; Butler, P. E. Hirudo medicinalis and the plastic surgeon Br. J. Plast. Surg. 2004, 57, 348-353
4. Haycraft, J. B. On the action of a secretion obtained from the medical leech on the coagulation of the blood Proc. R. Soc. London, Ser. B 1884, 36, 478-487
5. Jacobj, C. Über Hirudin Dtsch. Med. Wochenschr. 1904, 33, 1786-1787
6. Dodt, J.; Seemüller, U.; Maschler, R.; Fritz, H. The complete covalent structure of hirudin. Localization of the disulfide bonds Biol. Chem. Hoppe-Seyler 1985, 366, 379-385
7. Scharf, M.; Engels, J.; Tripier, D. Primary structures of new iso-hirudins FEBS Lett. 1989, 255, 105-110
8. Harvey, R. P.; Degryse, E.; Stefani, L.; Schamber, F.; Cazenave, J. P.; Courtney, M.; Tolstoshev, P.; Lecocq, J. P. Cloning and expression of a cDNA coding for the anticoagulant hirudin from the bloodsucking leech, Hirudo medicinalis Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 1084-1088
9. Markwardt, F. Die isolierung und chemische charakterisierung des hirudins Hoppe-Seyler's Z. Physiol. Chem 1957, 308, 147-156
10. Markwardt, F. Hirudin, der blutgerinnungshemmende Wirkstoff des medizinischen Blutegels Blut 1958, 4, 161-170
11. Markwardt, F. Historical perspective of the development of thrombin inhibitors Pathophysiol. Haemostasis Thromb. 2002, 32, 15-22
12. Nowak, G.; Schrör, K. Hirudin, the long and stony way from an anticoagulant peptide in the saliva of medicinal leech to a recombinant drug and beyond. A historical piece Thromb. Haemostasis 2007, 98, 116-119
13. Clore, G. M.; Sukumaran, D. K.; Nilges, M.; Zarbock, J.; Gronenborn, A. M. The conformations of hirudin in solution: a study using nuclear magnetic resonance, distance geometry and restrained molecular dynamics EMBO J. 1987, 6, 529-537
14. Folkers, P. J. M.; Clore, G. M.; Driscoll, P. C.; Dodt, J.; Koehler, S.; Gronenborn, A. M. Solution structure of recombinant hirudin and the Lys-47→Glu mutants: a nuclear magnetic resonance and hybrid distance geometry-dynamical simulated annealing study Biochemistry 1989, 28, 2601-2617
15. Haruyama, H.; Wuethrich, K. Conformation of recombinant desulfatohirudin in aqueous solution determined by nuclear magnetic resonance Biochemistry 1989, 28, 4301-4312
16. Chatrenet, B.; Chang, J. Y. The disulfide folding pathway of hirudin elucidated by stop/go folding experiments J. Biol. Chem. 1993, 268, 20988-96
17. Koh, C. Y.; Kini, R. M. Molecular diversity of anticoagulants from haematophagous animals Thromb. Haemostasis 2009, 102, 437-453
18. Rydel, T. J.; Ravichandran, K. G.; Tulinsky, A.; Bode, W.; Huber, R.; Roitsch, C.; Fenton, J. W., 2nd. The structure of a complex of recombinant hirudin and human alpha-thrombin Science 1990, 249, 277-280
19. Rydel, T. J.; Tulinsky, A.; Bode, W.; Huber, R. Refined structure of the hirudin-thrombin complex J. Mol. Biol. 1991, 221, 583-601
20. Grütter, M. G.; Priestle, J. P.; Rahuel, J.; Grossenbacher, H.; Bode, W.; Hofsteenge, J.; Stone, S. R. Crystal structure of the thrombin-hirudin complex: a novel mode of serine protease inhibition EMBO J. 1990, 9, 2361-2365
21. Vitali, J.; Martin, P. D.; Malkowski, M. G.; Robertson, W. D.; Lazar, J. B.; Winant, R. C.; Johnson, P. H.; Edwards, B. F. The structure of a complex of bovine alpha-thrombin and recombinant hirudin at 2.8-Å resolution J. Biol. Chem. 1992, 267, 17670-17678
22. Fenton, J. W.; Bing, D. H. Thrombin active-site regions Semin. Thromb. Hemostasis 1986, 12, 200-208
23. Dodt, J.; Köhler, S.; Baici, A. Interaction of site specific hirudin variants with [alpha]-thrombin FEBS Lett. 1988, 229, 87-90
24. Johnson, P. H.; Sze, P.; Winant, R.; Payne, P. W.; Lazar, J. B. Biochemistry and genetic engineering of hirudin Semin. Thromb. Hemost. 1989, 15, 302-315
25. Braun, P. J.; Dennis, S.; Hofsteenge, J.; Stone, S. R. Use of site-directed mutagenesis to investigate the basis for the specificity of hirudin Biochemistry 1988, 27, 6517-6522
26. Degryse, E.; Acker, M.; Defreyn, G.; Bernat, A.; Maffrand, J. P.; Roitsch, C.; Courtney, M. Point mutations modifying the thrombin inhibition kinetics and antithrombotic activity in vivo of recombinant hirudin Protein Eng. 1989, 2, 459-465
27. Fortkamp, E.; Rieger, M.; Heisterberg-Moutses, G.; Schweitzer, S.; Sommer, R. Cloning and expression in Escherichia coli of a synthetic DNA for hirudin, the blood coagulation inhibitor in the leech DNA 1986, 5, 511-517
28. Loison, G.; Findeli, A.; Bernard, S.; Nguyen-Juilleret, M.; Marquet, M.; Riehl-Bellon, N.; Carvallo, D.; Guerra-Santos, L.; Brown, S. W.; Courtney, M.; Roitsch, C.; Lemoine, Y. Expression and secretion in S. cerevisiae of biologically active leech hirudin Bio/Technology 1988, 6, 72-77
29. Wallace, A.; Dennis, S.; Hofsteenge, J.; Stone, S. R. Contribution of the N-terminal region of hirudin to its interaction with thrombin Biochemistry 1989, 28, 10079-10084
30. Lazar, J. B.; Winant, R. C.; Johnson, P. H. Hirudin: amino-terminal residues play a major role in the interaction with thrombin J. Biol. Chem. 1991, 266, 685-688
31. Winant, R. C.; Lazar, J. B.; Johnson, P. H. Chemical modifications and amino acid substitutions in recombinant hirudin that increase hirudin-thrombin affinity Biochemistry 1991, 30, 1271-1277
32. Betz, A.; Hofsteenge, J.; Stone, S. R. Interaction of the N-terminal region of hirudin with the active-site cleft of thrombin Biochemistry 1992, 31, 4557-4562
33. De Filippis, V.; Vindigni, A.; Altichieri, L.; Fontana, A. Core domain of hirudin from the leech Hirudinaria manillensis: chemical synthesis, purification, and characterization of a Trp3 analog of fragment 1-47 Biochemistry 1995, 34, 9552-9564
34. De Filippis, V.; Quarzago, D.; Vindigni, A.; Di Cera, E.; Fontana, A. Synthesis and characterization of more potent analogues of hirudin fragment 1-47 containing non-natural amino acids Biochemistry 1998, 37, 13507-13515
35. De Filippis, V.; Russo, I.; Vindigni, A.; Di Cera, E.; Salmaso, S.; Fontana, A. Incorporation of noncoded amino acids into the N-terminal domain 1-47 of hirudin yields a highly potent and selective thrombin inhibitor Protein Sci. 1999, 8, 2213-2217
36. De Filippis, V.; Colombo, G.; Russo, I.; Spadari, B.; Fontana, A. Probing the hirudin-thrombin interaction by incorporation of noncoded amino acids and molecular dynamics simulation Biochemistry 2002, 41, 13556-13569
37. Betz, A.; Hopkins, P. C.; Le Bonniec, B. F.; Stone, S. R. Contribution of interactions with the core domain of hirudin to the stability of its complex with thrombin Biochem. J. 1994, 298, 507-510
38. Chang, J. Y. Production, properties, and thrombin inhibitory mechanism of hirudin amino-terminal core fragments J. Biol. Chem. 1990, 265, 22159-22166
39. Chang, J. Y.; Ngai, P. K.; Rink, H.; Dennis, S.; Schlaeppi, J. M. The structural elements of hirudin which bind to the fibrinogen recognition site of thrombin are exclusively located within its acidic C-terminal tail FEBS Lett. 1990, 261, 287-290
40. Chang, J. Y. The hirudin-binding site of human alpha-thrombin. Identification of lysyl residues which participate in the combining site of hirudin-thrombin complex J. Biol. Chem. 1989, 264, 7141-7146
41. Dodt, J.; Machleidt, W.; Seemüller, U.; Maschler, R.; Fritz, H. Isolation and characterization of hirudin isoinhibitors and sequence analysis of hirudin PA Biol. Chem. Hoppe-Seyler 1986, 367, 803-811
42. Stone, S. R.; Hofsteenge, J. Kinetics of the inhibition of thrombin by hirudin Biochemistry 1986, 25, 4622-4628
43. Maraganore, J. M.; Chao, B.; Joseph, M. L.; Jablonski, J.; Ramachandran, K. L. Anticoagulant activity of synthetic hirudin peptides J. Biol. Chem. 1989, 264, 8692-8698
44. Liu, C. C.; Brustad, E.; Liu, W.; Schultz, P. G. Crystal structure of a biosynthetic sulfo-hirudin complexed to thrombin J. Am. Chem. Soc. 2007, 129, 10648-10649
45. Stone, S. R.; Dennis, S.; Hofsteenge, J. Quantitative evaluation of the contribution of ionic interactions to the formation of the thrombin-hirudin complex Biochemistry 1989, 28, 6857-6863
46. Myles, T.; Le Bonniec, B. F.; Betz, A.; Stone, S. R. Electrostatic steering and ionic tethering in the formation of thrombin-hirudin complexes: The role of the thrombin anion-binding exosite-I Biochemistry 2001, 40, 4972-4979
47. Betz, A.; Hofsteenge, J.; Stone, S. R. Ionic interactions in the formation of the thrombin-hirudin complex Biochem. J. 1991, 275, 801-803
48. Krstenansky, J. L.; Owen, T. J.; Yates, M. T.; Mao, S. J. T. Anticoagulant peptides: nature of the interaction of the C-terminal region of hirudin with a noncatalytic binding site on thrombin J. Med. Chem. 1987, 31, 1688-1691
49. Owen, T. J.; Krstenansky, J. L.; Yates, M. T.; Mao, S. J. T. N-Terminal requirements of small peptide anticoagulants based on hirudin(54-65) J. Med. Chem. 1988, 31, 1009-1011
50. Mao, S. J. T.; Yates, M. T.; Owen, T. J.; Krstenansky, J. L. Interaction of hirudin with thrombin: identification of a minimal binding domain of hirudin that inhibits clotting activity Biochemistry 1988, 27, 8170-8173
51. Betz, A.; Hofsteenge, J.; Stone, S. R. Role of interactions involving C-terminal nonpolar residues of hirudin in the formation of the thrombin-hirudin complex Biochemistry 1991, 30, 9848-9853
52. Krstenansky, J. L.; Mao, S. J. T. Antithrombin properties of C-terminus of hirudin using synthetic unsulfated N[alpha]-acetyl-hirudin45-65 FEBS Lett. 1987, 211, 10-16
53. Naski, M. C.; Fenton, J. W. d.; Maraganore, J. M.; Olson, S. T.; Shafer, J. A. The COOH-terminal domain of hirudin. An exosite-directed competitive inhibitor of the action of alpha-thrombin on fibrinogen J. Biol. Chem. 1990, 265, 13484-13489
54. Krstenansky, J. L.; Owen, T. J.; Yates, M. T.; Mao, S. J. T. The C-terminal binding domain of hirullin P18: antithrombin activity and comparison to hirudin peptides FEBS Lett. 1990, 269, 425-429
55. Vu, T. K.; Hung, D. T.; Wheaton, V. I.; Coughlin, S. R. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation Cell 1991, 64, 1057-1068
56. Jandrot-Perrus, M.; Huisse, M. G.; Krstenansky, J. L.; Bezeaud, A.; Guillin, M. C. Effect of the hirudin carboxy-terminal peptide 54-65 on the interaction of thrombin with platelets Thromb. Haemostasis 1991, 66, 300-305
57. Tsiang, M.; Lentz, S. R.; Dittman, W. A.; Wen, D.; Scarpati, E. M.; Sadler, J. E. Equilibrium binding of thrombin to recombinant human thrombomodulin: effect of hirudin, fibrinogen, factor Va, and peptide analogs Biochemistry 1990, 29, 10602-10612
58. Jackman, M. P.; Parry, M. A.; Hofsteenge, J.; Stone, S. R. Intrinsic fluorescence changes and rapid kinetics of the reaction of thrombin with hirudin J. Biol. Chem. 1992, 267, 15375-15383
59. Konno, S.; Fenton, J. W.; Villanueva, G. B. Analysis of the secondary structure of hirudin and the mechanism of its interaction with thrombin Arch. Biochem. Biophys. 1988, 267, 158-166
60. Electricwala, A.; Sawyer, R. T.; Jones, C. P.; Atkinson, T. Isolation of thrombin inhibitor from the leech Hirudinaria manillensis Blood Coagulation Fibrinolysis 1991, 2, 83-89
61. Electricwala, A.; Hartwell, R.; Scawen, M. D.; Atkinson, T. The complete amino acid sequence of a hirudin variant from the leech Hirudinaria manillensis J. Protein Chem. 1993, 12, 365-370
62. Nicastro, G.; Baumer, L.; Bolis, G.; Tato, M. NMR solution structure of a novel hirudin variant HM2, N-terminal 1-47 and N64→V + G mutant Biopolymers 1997, 41, 731-749
63. Steiner, V.; Knecht, R.; Boernsen, K. O.; Gassmann, E.; Stone, S. R.; Raschdorf, F.; Schlaeppi, J. M.; Maschler, R. Primary structure and function of novel O-glycosylated hirudins from the leech Hirudinaria manillensis Biochemistry 1992, 31, 2294-2298
64. Scacheri, E.; Nitti, G.; Valsasina, B.; Orsini, G.; Visco, C.; Ferrera, M.; Sawyer, R. T.; Sarmientos, P. Novel hirudin variants from the leech Hirudinaria manillensis. Amino acid sequence, cDNA cloning and genomic organization Eur. J. Biochem. 1993, 214, 295-304
65. Steiner, V.; Knecht, R.; Gruetter, M.; Raschdorf, F.; Gassmann, E.; Maschler, R. Isolation and purification of novel hirudins from the leech Hirudinaria manillensis by high-performance liquid chromatography J. Chromatogr. 1990, 530, 273-282
66. Vindigni, A.; De Filippis, V.; Zanotti, G.; Visco, C.; Orsini, G.; Fontana, A. Probing the structure of hirudin from Hirudinaria manillensis by limited proteolysis Eur. J. Biochem. 1994, 226, 323-333
67. Vankhede, G. N.; Gomase, V. S.; Deshmukh, S. V.; Chikhale, N. J. Prediction of antigenic epitope of hirudin from Poecilobdella viridis J. Comp. Toxicol. Physiol. 2005, 2, 110-118
68. Strube, K. H.; Kroger, B.; Bialojan, S.; Otte, M.; Dodt, J. Isolation, sequence analysis, and cloning of haemadin. An anticoagulant peptide from the Indian leech J. Biol. Chem. 1993, 268, 8590-8595
69. Richardson, J. L.; Kroger, B.; Hoeffken, W.; Sadler, J. E.; Pereira, P.; Huber, R.; Bode, W.; Fuentes-Prior, P. Crystal structure of the human alpha-thrombin-haemadin complex: an exosite II-binding inhibitor EMBO J. 2000, 19, 5650-5660
70. Richardson, J. L.; Fuentes-Prior, P.; Sadler, J. E.; Huber, R.; Bode, W. Characterization of the residues involved in the human alpha-thrombin-haemadin complex: an exosite II-binding inhibitor Biochemistry 2002, 41, 2535-2542
71. Malecha, J.; Verger-Bocquet, M.; Tramu, G. Mise en évidence et évolution, au cours du cycle biologique, de neurones producteurs d'une substance apparentée à la motiline porcine dans le ganglion supraoesophagien de la sangsue Theromyzon tessulatum Can. J. Zool. 1989, 67, 636-640
72. Salzet, M.; Chopin, V.; Baert, J.-l.; Matias, I.; Malecha, J. Theromin, a novel leech thrombin inhibitor J. Biol. Chem. 2000, 275, 30774-30780
73. Hong, S. J.; Kang, K. W. Purification of granulin-like polypeptide from the blood-sucking leech, Hirudo nipponia Protein Expression Purif. 1999, 16, 340-346
74. Chopin, V.; Salzet, M.; Baert, J.-l.; Vandenbulcke, F.; Sautiere, P.-E.; Kerckaert, J.-P.; Malecha, J. Therostasin, a novel clotting factor Xa inhibitor from the rhynchobdellid leech, Theromyzon tessulatum J. Biol. Chem. 2000, 275, 32701-32707
75. Chopin, V.; Stefano, G. B.; Salzet, M. Amino-acid-sequence determination and biological activity of tessulin, a naturally occurring trypsin-chymotrypsin inhibitor isolated from the leech Theromyzon tessulatum Eur. J. Biochem. 1998, 258, 662-668 (Pubitemid 28557931)
76. Mittl, P. R. E.; Marco, S. D.; Fendrich, G.; Pohlig, G.; Heim, J.; Sommerhoff, C.; Fritz, H.; Priestle, J. P.; Grütter, M. G. A new structural class of serine protease inhibitors revealed by the structure of the hirustasin-kallikrein complex Structure 1997, 5, 253-264
77. Tuszynski, G. P.; Gasic, T. B.; Gasic, G. J. Isolation and characterization of antistasin. An inhibitor of metastasis and coagulation J. Biol. Chem. 1987, 262, 9718-9723
78. Nutt, E.; Gasic, T.; Rodkey, J.; Gasic, G. J.; Jacobs, J. W.; Friedman, P. A.; Simpson, E. The amino acid sequence of antistasin. A potent inhibitor of factor Xa reveals a repeated internal structure J. Biol. Chem. 1988, 263, 10162-10167
79. Condra, C.; Nutt, E.; Petroski, C. J.; Simpson, E.; Friedman, P. A.; Jacobs, J. W. Isolation and structural characterization of a potent inhibitor of coagulation factor Xa from the leech Haementeria ghilianii Thromb. Haemostasis 1989, 61, 437-441
80. Brankamp, R. G.; Blankenship, D. T.; Sunkara, P. S.; Cardin, A. D. Ghilantens: anticoagulant-antimetastatic proteins from the South American leech, Haementeria ghilianii J. Lab. Clin. Med. 1990, 115, 89-97
81. Blankenship, D. T.; Brankamp, R. G.; Manley, G. D.; Cardin, A. D. Amino acid sequence of ghilanten: anticoagulant-antimetastatic principle of the South American leech Biochem. Biophys. Res. Commun. 1990, 166, 1384-1389
82. Holstein, T. W.; Mala, C.; Kurz, E.; Bauer, K.; Greber, M.; David, C. N. The primitive metazoan Hydra expresses antistasin, a serine protease inhibitor of vertebrate blood coagulation: cDNA cloning, cellular localisation and developmental regulation FEBS Lett. 1992, 309, 288-292
83. Jung, H. I.; Kim, S. I.; Ha, K.-S.; Joe, C. O.; Kang, K. W. Isolation and characterization of guamerin, a new human leukocyte elastase inhibitor from Hirudo nipponia J. Biol. Chem. 1995, 270, 13879-13884
84. Bruin, E. C.; Roem, D.; Bulder, I.; Dieker, M.; Voerman, G.; Hack, C. E. Production, purification and characterisation of recombinant fahsin, a novel antistasin-type proteinase inhibitor FEMS Yeast Res. 2005, 5, 1069-1077
85. Sollner, C.; Mentele, R.; Eckerskorn, C.; Fritz, H.; Sommerhoff, C. P. Isolation and characterization of hirustasin, an antistasin-type serine-proteinase inhibitor from the medical leech Hirudo medicinalis Eur. J. Biochem. 1994, 219, 937-943
86. Kim, D. R.; Kang, K. W. Amino acid sequence of piguamerin, an antistasin-type protease inhibitor from the blood sucking leech Hirudo nipponia Eur. J. Biochem. 1998, 254, 692-697
87. Lapatto, R.; Krengel, U.; Schreuder, H. A.; Arkema, A.; de Boer, B.; Kalk, K. H.; Hol, W. G. J.; Grootenhuis, P. D. J.; Mulders, J. W. M.; Dijkema, R.; Theunissen, H. J. M.; Dijkstra, B. W. X-ray structure of antistasin at 1.9 Å resolution and its modelled complex with blood coagulation factor Xa EMBO J. 1997, 16, 5151-5161
88. Usón, I.; Sheldrick, G. M.; Fortelle, E. d. L.; Bricogne, G.; Marco, S. D.; Priestle, J. P.; Grütter, M. G.; Mittl, P. R. E. The 1.2 Å crystal structure of hirustasin reveals the intrinsic flexibility of a family of highly disulphide-bridged inhibitors Structure 1999, 7, 55-63
89. Rester, U.; Bode, W.; Moser, M.; Parry, M. A. A.; Huber, R.; Auerswald, E. Structure of the complex of the antistasin-type inhibitor bdellastasin with trypsin and modelling of the bdellastasin-microplasmin system J. Mol. Biol. 1999, 293, 93-106
90. Kim, H.; Chu, T. T. T.; Kim, D. Y.; Kim, D. R.; Nguyen, C. M. T.; Choi, J.; Lee, J.-R.; Hahn, M.-J.; Kim, K. K. The crystal structure of guamerin in complex with chymotrypsin and the development of an elastase-specific inhibitor J. Mol. Biol. 2008, 376, 184-192
91. Dunwiddie, C.; Thornberry, N. A.; Bull, H. G.; Sardana, M.; Friedman, P. A.; Jacobs, J. W.; Simpson, E. Antistasin, a leech-derived inhibitor of factor Xa. Kinetic analysis of enzyme inhibition and identification of the reactive site J. Biol. Chem. 1989, 264, 16694-16699
92. Palladino, L. O.; Tung, J.-S.; Dunwiddie, C.; Alves, K.; Lenny, A. B.; Przysiecki, C.; Lehman, D.; Nutt, E.; Cuca, G. C.; Law, S. W.; Silberklang, M.; Ellis, R. W.; Mark, G. E. Expression and characterization of the N-terminal half of antistasin, an anticoagulant protein derived from the leech Haementeria officinalis Protein Expression Purif. 1991, 2, 37-42
93. Hofmann, K. J.; Nutt, E. M.; Dunwiddie, C. Site-directed mutagenesis of the leech-derived factor Xa inhibitor antistasin. Probing of the reactive site Biochem. J. 1992, 287, 943-949
94. Theunissen, H. J. M.; Dijkema, R.; Swinkels, J. C.; de Poorter, T. L.; Vink, P. M. F.; Dinther, T. G. V. Mutational analysis of antistasin, an inhibitor of blood coagulation factor Xa derived from the Mexican leech Haementeria officinalis Thromb. Res. 1994, 75, 41-50
95. Dunwiddie, C. T.; Vlasuk, G. P.; Nutt, E. M. The hydrolysis and resynthesis of a single reactive site peptide bond in recombinant antistasin by coagulation factor Xa Arch. Biochem. Biophys. 1992, 294, 647-653
96. Zeymer, U. Recombinant hirudins: an overview of recent developments BioDrugs 1998, 10, 425-436
97. Markwardt, F. The development of hirudin as an antithrombotic drug Thromb. Res. 1994, 74, 1-23
98. Greinacher, A.; Lubenow, N. Recombinant hirudin in clinical practice: focus on lepirudin Circulation 2001, 103, 1479-1484
99. Warkentin, T. E. Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban Thromb. Res. 2003, 110, 73-82
100. Greinacher, A.; Warkentin, T. E. The direct thrombin inhibitor hirudin Thromb. Haemostasis 2008, 99, 819-829
101. Knapp, A.; Degenhardt, T.; Dodt, J. Hirudisins. Hirudin-derived thrombin inhibitors with disintegrin activity J. Biol. Chem. 1992, 267, 24230-24234
102. Song, X.; Mo, W.; Liu, X.; Zhu, L.; Yan, X.; Song, H.; Dai, L. The NMR solution structure of recombinant RGD-hirudin Biochem. Biophys. Res. Commun. 2007, 360, 103-108
103. Mo, W.; Zhang, Y.-L.; Chen, H.-S.; Wang, L.-S.; Song, H.-Y. A novel hirudin derivative characterized with anti-platelet aggregations and thrombin inhibition J. Thromb. Thrombolysis 2009, 28, 230-237
104. Sheffield, W. P.; Eltringham-Smith, L. J.; Gataiance, S.; Bhakta, V. A long-lasting, plasmin-activatable thrombin inhibitor aids clot lysis in vitro and does not promote bleeding in vivo Thromb. Haemostasis 2009, 101, 867-877
105. Lian, Q.; Szarka, S. J.; Ng, K. K. S.; Wong, S.-L. Engineering of a staphylokinase-based fibrinolytic agent with antithrombotic activity and targeting capability toward thrombin-rich fibrin and plasma clots J. Biol. Chem. 2003, 278, 26677-26686
106. Kowalski, M.; Brown, G.; Bieniasz, M.; Oszajca, K.; Chabielska, E.; Pietras, T.; Szemraj, Z.; Makandjou-Ola, E.; Bartkowiak, J.; Szemraj, J. Cloning and expression of a new recombinant thrombolytic and anthithrombotic agent-a staphylokinase variant Acta Biochim. Pol. 2009, 56, 41-53
107. Maraganore, J. M.; Bourdon, P.; Jablonski, J.; Ramachandran, K. L.; Fenton, J. W. d. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin Biochemistry 1990, 29, 7095-7101
108. Witting, J. I.; Bourdon, P.; Brezniak, D. V.; Maraganore, J. M.; Fenton, J. W. d. Thrombin-specific inhibition by and slow cleavage of hirulog-1 Biochem. J. 1992, 283, 737-743
109. Witting, J. I.; Bourdon, P.; Maraganore, J. M.; Fenton, J. W. d. Hirulog-1 and -B2 thrombin specificity Biochem. J. 1992, 287, 663-664
110. Parry, M. A.; Maraganore, J. M.; Stone, S. R. Kinetic mechanism for the interaction of hirulog with thrombin Biochemistry 1994, 33, 14807-14814
111. Christophe, T.; Christel, G.; Serge, S.; Tony, J. V.; Jean-Luc, F. Synthesis of a new bivalent hirudin analog (hirufos), which includes a stable 4′-phosphono- l -phenylalanine mimic of (l -tyrosine O4-sulfate)-63 Helv. Chim. Acta 1994, 77, 679-684
112. Skordalakes, E.; Elgendy, S.; Goodwin, C. A.; Green, D.; Scully, M. F.; Kakkar, V. V.; Freyssinet, J.-M.; Dodson, G.; Deadman, J. J. Bifunctional peptide boronate inhibitors of thrombin: crystallographic analysis of inhibition enhanced by linkage to an exosite 1 binding peptide Biochemistry 1998, 37, 14420-14427
113. Su, Z.; Vinogradova, A.; Koutychenko, A.; Tolkatchev, D.; Ni, F. Rational design and selection of bivalent peptide ligands of thrombin incorporating P4-P1 tetrapeptide sequences: from good substrates to potent inhibitors Protein Eng., Des. Sel. 2004, 17, 647-657
114. Kline, T.; Hammond, C.; Bourdon, P.; Maraganore, J. M. Hirulog peptides with scissile bond replacements resistant to thrombin cleavage Biochem. Biophys. Res. Commun. 1991, 177, 1049-1055
115. DiMaio, J.; Ni, F.; Gibbs, B.; Konishi, Y. A new class of potent thrombin inhibitors that incorporates a scissile pseudopeptide bond FEBS Lett. 1991, 282, 47-52
116. DiMaio, J.; Ni, F.; Gibbs, B.; Konishi, Y. Synthesis of a homologous series of ketomethylene arginyl pseudodipeptides and application to low molecular weight hirudin-like thrombin inhibitors J. Med. Chem. 1992, 35, 3331-3341
117. Krishnan, R.; Tulinsky, A.; Vlasuk, G. P.; Pearson, D.; Vallar, P.; Bergum, P.; Brunck, T. K.; Ripka, W. C. Synthesis, structure, and structure-activity relationships of divalent thrombin inhibitors containing an alpha-keto-amide transition-state mimetic Protein Sci. 1996, 5, 422-433
118. Steinmetzer, T.; Batdordshjin, M.; Pineda, F.; Seyfarth, L.; Vogel, A.; Reissmann, S.; Hauptmann, J.; Stürzebecher, J. New bivalent thrombin inhibitors with N(alpha)(methyl)arginine at the P1-position Biol. Chem. Hoppe-Seyler 2000, 381, 603-610
119. Friedrich, R.; Steinmetzer, T.; Huber, R.; Stürzebecher, J.; Bode, W. The methyl group of N[alpha](Me)Arg-containing peptides disturbs the active-site geometry of thrombin, impairing efficient cleavage J. Mol. Biol. 2002, 316, 869-874
120. Lombardi, A.; Nastri, F.; Della Morte, R.; Rossi, A.; De Rosa, A.; Staiano, N.; Pedone, C.; Pavone, V. Rational design of true hirudin mimetics: synthesis and characterization of multisite-directed alpha-thrombin inhibitors J. Med. Chem. 1996, 39, 2008-2017
121. Cappiello, M.; Vilardo, P. G.; Del Corso, A.; Mura, U. Hirunorms, novel hirudin-like direct thrombin inhibitors Gen. Pharmacol. 1998, 30, 565-568 (Pubitemid 28102835)
122. Tsuda, Y.; Cygler, M.; Gibbs, B. F.; Pedyczak, A.; Féthiè re, J.; Yue, S. Y.; Konishi, Y. Design of potent bivalent thrombin inhibitors based on hirudin sequence: incorporation of nonsubstrate-type active site inhibitors Biochemistry 1994, 33, 14443-14451
123. Slon-Usakiewicz, J. J.; Purisima, E.; Tsuda, Y.; Sulea, T.; Pedyczak, A.; Fethiere, J.; Cygler, M.; Konishi, Y. Nonpolar interactions of thrombin S′ subsites with its bivalent inhibitor: methyl scan of the inhibitor linker Biochemistry 1997, 36, 13494-13502
124. Skrzypczak-Jankun, E.; Carperos, V. E.; Ravichandran, K. G.; Tulinsky, A.; Westbrook, M.; Maraganore, J. M. Structure of the hirugen and hirulog 1 complexes of alpha-thrombin J. Mol. Biol. 1991, 221, 1379-1393
125. Qiu, X.; Padmanabhan, K. P.; Carperos, V. E.; Tulinsky, A.; Kline, T.; Maraganore, J. M.; Fenton, J. W. d. Structure of the hirulog 3-thrombin complex and nature of the S′ subsites of substrates and inhibitors Biochemistry 1992, 31, 11689-11697
126. Zdanov, A.; Wu, S.; DiMaio, J.; Konishi, Y.; Li, Y.; Wu, X.; Edwards, B. F.; Martin, P. D.; Cygler, M. Crystal structure of the complex of human alpha-thrombin and nonhydrolyzable bifunctional inhibitors, hirutonin-2 and hirutonin-6 Proteins 1993, 17, 252-265
127. Rehse, P. H.; Steinmetzer, T.; Li, Y.; Konishi, Y.; Cygler, M. Crystal structure of a peptidyl pyridinium methyl ketone inhibitor with thrombin Biochemistry 1995, 34, 11537-11544
128. Lombardi, A.; De Simone, G.; Nastri, F.; Galdiero, S.; Della Morte, R.; Staiano, N.; Pedone, C.; Bolognesi, M.; Pavone, V. The crystal structure of alpha-thrombin-hirunorm IV complex reveals a novel specificity site recognition mode Protein Sci. 1999, 8, 91-95
129. De Simone, G.; Lombardi, A.; Galdiero, S.; Nastri, F.; Della Morte, R.; Staiano, N.; Pedone, C.; Bolognesi, M.; Pavone, V. Hirunorms are true hirudin mimetics. The crystal structure of human alpha-thrombin-hirunorm V complex Protein Sci. 1998, 7, 243-253
130. Féthière, J.; Tsuda, Y.; Coulombe, R.; Konishi, Y.; Cygler, M. Crystal structure of two new bifunctional nonsubstrate type thrombin inhibitors complexed with human alpha-thrombin Protein Sci. 1996, 5, 1174-1183
131. Slon-Usakiewicz, J. J.; Sivaraman, J.; Li, Y.; Cygler, M.; Konishi, Y. Design of P1′ and P3′ residues of trivalent thrombin inhibitors and their crystal structures Biochemistry 2000, 39, 2384-2391
132. Church, F. C.; Phillips, J. E.; Woods, J. L. Chimeric antithrombin peptide. Characterization of an Arg-Gly-Asp (RGD)- and hirudin carboxyl terminus-containing synthetic peptides J. Biol. Chem. 1991, 266, 11975-11979
133. Leblond, L.; DiMaio, J.; Winocour, P. D. Insertion of the Asp-Ser/Phe sequence in the P′ position of hirutonin provides molecules having both antithrombin and disintegrin activity Thromb. Res. 1999, 93, 171-181
134. van Wyk, V.; Leblond, L.; Winocour, P. D.; Devine, D. V.; Gyongyossy-Issa, M. I. C. Incorporation of an Asp-Ser sequence to form an RGDS-like motif in hirutonin: the effect on in vitro platelet function Thromb. Res. 2000, 99, 343-352
135. Cirillo, R.; Lippi, A.; Subissi, A.; Agnelli, G.; Criscuoli, M. Experimental pharmacology of hirunorm: a novel synthetic peptide thrombin inhibitor Thromb. Haemostasis 1996, 76, 384-392 (Pubitemid 26373532)
136. Finkle, C. D., St; Pierre, A.; Leblond, L.; Deschenes, I.; DiMaio, J.; Winocour, P. D. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis: comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban Thromb. Haemostasis 1998, 79, 431-438
137. McClanahan, T. B.; Ignasiak, D. P.; Juneau, P.; Finkle, C.; Winocour, P. D.; Gallagher, K. P. Antithrombotic effects of BCH 2763, a new direct thrombin inhibitor, in a canine model of venous thrombosis J. Thromb. Thrombolysis 1999, 7, 301-306
138. Deschênes, I.; Finkle, C. D.; Winocour, P. D. Effective use of BCH-2763, a new potent injectable direct thrombin inhibitor, in combination with tissue plasminogen activator (tPA) in a rat arterial thrombolysis model Thromb. Haemostasis 1998, 80, 186-191
139. Kelly, A. B.; Maraganore, J. M.; Bourdon, P.; Hanson, S. R.; Harker, L. A. Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 6040-6044
140. White, H. D.; Aylward, P. E.; Frey, M. J.; Adgey, A. A. J.; Nair, R.; Hillis, W. S.; Shalev, Y.; Brown, M. A.; French, J. K.; Collins, R.; Maraganore, J.; Adelman, B. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO) Circulation 1997, 96, 2155-2161
141. Bittl, J. A.; Chaitman, B. R.; Feit, F.; Kimball, W.; Topol, E. J. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the bivalirudin angioplasty study Am. Heart J. 2001, 142, 952-959
142. Chew, D. P.; Bhatt, D. L.; Kimball, W.; Henry, T. D.; Berger, P.; McCullough, P. A.; Feit, F.; Bittl, J. A.; Lincoff, A. M. Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials Am. J. Cardiol. 2003, 92, 919-923
143. Sinnaeve, P. R.; Simes, J.; Yusuf, S.; Garg, J.; Mehta, S.; Eikelboom, J.; Bittl, J. A.; Serruys, P.; Topol, E. J.; Granger, C. B. Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention Eur. Heart J. 2005, 26, 2396-2403
144. Warkentin, T. E.; Greinacher, A.; Koster, A. Bivalirudin Thromb. Haemostasis 2008, 99, 830-839
145. Stone, G. W.; McLaurin, B. T.; Cox, D. A.; Bertrand, M. E.; Lincoff, A. M.; Moses, J. W.; White, H. D.; Pocock, S. J.; Ware, J. H.; Feit, F.; Colombo, A.; Aylward, P. E.; Cequier, A. R.; Darius, H.; Desmet, W.; Ebrahimi, R.; Hamon, M.; Rasmussen, L. H.; Rupprecht, H.-J.; Hoekstra, J.; Mehran, R.; Ohman, E. M. (ACUITY Investigators) Bivalirudin for patients with acute coronary syndromes. N. Engl. J. Med. 2006, 355, 2203 - 2216.
146. Manoukian, S. V.; Feit, F.; Mehran, R.; Voeltz, M. D.; Ebrahimi, R.; Hamon, M.; Dangas, G. D.; Lincoff, A. M.; White, H. D.; Moses, J. W.; King, S. B., III; Ohman, E. M.; Stone, G. W. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY trial J. Am. Coll. Cardiol. 2007, 49, 1362-1368
147. Peters, D.; Kastantin, M.; Kotamraju, V. R.; Karmali, P. P.; Gujraty, K.; Tirrell, M.; Ruoslahti, E. Targeting atherosclerosis by using modular, multifunctional micelles Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 9815-9819